AI-generated price forecast for NewAmsterdam Pharma Company NV (NAMS) across 1-hour, 4-hour, daily and weekly horizons — updated continuously, with a public accuracy track record.
As of September 2026: K3vl4r's AI model currently reads NAMS as 1/1 bearish across its horizons (0 of 1 timeframes pointing up), with a last price of 22.30. See our public, auditable track record →
Last price
22.30
AI outlook
1/1 bearish
Timeframes up
0 / 1
| Horizon | Direction | Projected move (end of horizon) | Bullish prob. |
|---|---|---|---|
| 1-hour | — | — | — |
| 4-hour~4 weeks out | — | — | — |
| Daily~4 months out | ▼ Down | -6.76% | — |
| Weekly~1.8 years out | — | — | — |
From the market-news feed the forecasts are read against.
🔒
See the full NAMS forecast
Interactive forecast chart, price targets, and Monte-Carlo confidence bands — plus the daily AI Top Picks book. Free to start, no card required.
Create a free account →Already have one? Log in
K3vl4r's AI model currently reads NAMS as 1/1 bearish — 0 of 1 forecast horizons point up, so the overall read is leaning to the downside. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.
K3vl4r's model projects NAMS toward $25.38 over the next ~4 months, a -0.1% move from $25.40. Projections update continuously as new data arrives and are inherently uncertain. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.
Part of Healthcare forecasts — browse the full sector.
Or see the full NAMS price prediction (2027–2040), or the forecast for today, tomorrow and this week.
Curious how this is generated? Read how K3vl4r forecasts — the model, the confidence bands, and what we deliberately do not claim.
K3vl4r publishes a public, auditable track record of its Daily Top Picks — see the live results.
Forecasts are model-generated estimates for informational purposes only and are not financial advice. Markets are risky; past accuracy does not guarantee future results. See our Risk Disclosure.